MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST)
Clinical trials for MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) trials appear
Sign up with your email to follow new studies for MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare sarcomas: immune drug plus chemo tested
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy can help shrink or control advanced soft tissue sarcomas that cannot be removed by surgery. About 45 adults aged 18-75 with certain sarcoma types will receive the combination as their fir…
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Personalized cell therapy trial opens for kids with rare tumors
Disease control Recruiting nowThis study tests a new treatment called afamitresgene autoleucel in children and young adults aged 2 to 21 with advanced cancers like synovial sarcoma, neuroblastoma, and osteosarcoma. The treatment uses the patient's own immune cells, modified to target a protein called MAGE-A4 …
Matched conditions: MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST)
Phase: PHASE1, PHASE2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated May 11, 2026 20:41 UTC